What caused the BAYN.DE stock drop on 29 Jan 2026?

BAYN.DE stock fell **5.81%** on active volume as investors reacted to U.S. litigation updates and clinical trial news, increasing short-term uncertainty while volume hit **3,950,249.00** shares on XETRA.

What is Meyka AI’s current rating for BAYN.DE stock?

Meyka AI rates BAYN.DE with a score of **64.24 / 100** (Grade B) and a suggestion to **HOLD**, based on benchmark and sector comparisons, financial growth, metrics, and forecasts.

How do Meyka AI forecasts compare to BAYN.DE stock price now?

Meyka AI's model projects **€42.50** (monthly) and **€37.81** (quarterly), implying downside of **-3.45%** and **-14.10%** from the current **€44.02** close; forecasts are model-based and not guarantees.

What are the main risks for BAYN.DE stock holders?

Primary risks include Roundup litigation outcomes, leverage (debt-to-equity **1.34**), and biotech/regulatory setbacks; opportunities include pipeline progress and crop science investments.

DE Stocks

BAYN.DE falls 5.81% to €44.02 on 29 Jan 2026: heavy XETRA volume signals active trading ahead

ByHuzaifa Zahoor January 30, 2026January 30, 2026

BAYN.DE stock closed the XETRA session on 29 Jan 2026 at €44.02, down 5.81% on heavy liquidity as investors reacted to legal and clinical updates. Volume reached 3,950,249.00 shares versus an average of 3,292,466.00, placing Bayer AG among the market’s most active names in Germany. The slide followed a string of news items, including U.S. litigation developments and clinical trial presentations, both of which directly affect valuation and near-term volatility for Bayer AG on XETRA.